Related Experiment Videos
Influence of lipids metabolism on platelet activation in vivo
Insights
Simfibrate, a lipid-lowering drug, reduced platelet activation in ischemic heart disease patients. This suggests hyperlipidemia enhances platelet aggregation, and simfibrate may counteract this effect via the arachidonic pathway.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Ischemic heart disease (IHD) involves platelet activation.
- Hyperlipidemia is a risk factor for cardiovascular events.
- Platelet function is crucial in atherothrombosis.
Purpose of the Study:
- To investigate the effect of simfibrate on platelet aggregability and related markers in IHD patients.
- To explore the impact of simfibrate on lipid profiles and platelet activation in hyperlipidemic individuals.
- To elucidate the in vitro mechanisms of platelet activation and simfibrate's potential anti-platelet effects.
Main Methods:
- Assessed platelet aggregability and Factor VIII-related antigen (F.VIIIR:AG) levels in IHD patients undergoing isometric exercise.
- Administered simfibrate to IHD patients and hyperlipidemic subjects, monitoring lipid profiles and platelet malondialdehyde (MDA) production.
- Conducted in vitro studies exposing normal blood to a glass bead column to simulate atherosclerotic conditions and assess platelet activation markers like von Willebrand factor (vWF).
Main Results:
- Isometric exercise increased platelet aggregability and F.VIIIR:AG in IHD patients; simfibrate prevented these increases.
- Simfibrate treatment lowered serum total cholesterol (TC) and increased the HDL-C/TC ratio.
- In hyperlipidemic subjects, simfibrate reduced platelet MDA production alongside lipid profile improvements.
- In vitro, platelet aggregability and vWF/F.VIIIR:AG levels increased upon contact with a glass bead column.
Conclusions:
- Hyperlipidemia may promote in vivo platelet activation, potentially triggered by contact with atherosclerotic vessel surfaces.
- Simfibrate demonstrates an anti-platelet effect, possibly mediated through its influence on the platelet arachidonic acid pathway.
- These findings suggest simfibrate's potential therapeutic role in managing cardiovascular risk by modulating platelet activity and lipid metabolism.
Abstract:
Platelet aggregability and plasma factor VIII-related antigen (F. VIIIR:AG) level in 16 ischemic heart disease (IHD) patients were increased by isometric exercise and these changes were prevented by administration of a lipid lowering agent, simfibrate, a derivative of clofibrate. Serum total cholesterol (TC) level decreased and the high density lipoprotein-cholesterol (HDL-C)/TC ratio increased with the treatment. Another 7 hyperlipidemics were administered with simfibrate. Platelet malondialdehyde (MDA) production decreased with improvement in lipid profile. In an in vitro study, platelet aggregability and the plasma level of von Willebrand factor (vWF) and F.VIIIR:AG of normal citrated blood were increased by passing it through a glass bead column. Combining above results of the three separate studies, it would be suggested that hyperlipidemia might enhance platelet activation in vivo, which occurred through contact of platelets to atherosclerotic rough vessel surface. The anti-platelet effect of simfibrate might be mediated through its effect on arachidonic pathway in platelets.